DO YOU KNOW SOMEONE WITH

DIAMOND-BLACKFAN ANEMIA?



Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are conducting a research study with eltrombopag to help patients with Diamond-Blackfan anemia (DBA). Eltrombopag is a drug that can help patients with aplastic anemia, an acquired bone marrow failure syndrome. Whether it can also help patients with different, inherited bone marrow failures is a point of ongoing research at the NIH. This study will attempt to determine whether eltrombopag is safe and effective for patients with DBA.

STUDY INVOLVES:

- 1-2 visits to the NIH Clinical Center in Bethesda, Maryland before starting drug and then every 6 months while on drug
- Patients will take eltrombopag over a 6-month period
- Patients who exhibit improvements after 6 months of taking eltrombopag may be eligible to continue taking eltrombopag for up to 3 additional years

WHO CAN PARTICIPATE:

- Patients 2 years or older diagnosed with DBA
- Patients diagnosed with DBA who have not responded to therapy, have relapsed, and/or are unable to their tolerate current therapy
- Patients willing to take eltrombopag for a minimum of 6 months
- Patients willing to have their blood drawn every two weeks by your home physician

The NIH Clinical Center, America's research hospital, is in Bethesda, Maryland, on the Metro red line (Medical Center stop)

NIH Clinical Center Office of Patient Recruitment 1-800-411-1222 (800-877-8339 TTY/ASCII) Se habla español Email: PRPL@cc.nih.gov Online: <u>https://go.usa.gov/xdNyc</u> Refer to study #20-H-0021



and Blood Institute